NEURONETICS INC (STIM) Fundamental Analysis & Valuation

NASDAQ:STIM • US64131A1051

Current stock price

1.68 USD
-0.01 (-0.59%)
At close:
1.7 USD
+0.02 (+1.19%)
After Hours:

This STIM fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. STIM Profitability Analysis

1.1 Basic Checks

  • In the past year STIM has reported negative net income.
  • In the past year STIM has reported a negative cash flow from operations.
  • In the past 5 years STIM always reported negative net income.
  • STIM had a negative operating cash flow in each of the past 5 years.
STIM Yearly Net Income VS EBIT VS OCF VS FCFSTIM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -10M -20M -30M -40M

1.2 Ratios

  • With a Return On Assets value of -27.55%, STIM perfoms like the industry average, outperforming 44.38% of the companies in the same industry.
  • The Return On Equity of STIM (-174.27%) is worse than 74.33% of its industry peers.
Industry RankSector Rank
ROA -27.55%
ROE -174.27%
ROIC N/A
ROA(3y)-28.21%
ROA(5y)-27.7%
ROE(3y)-140.11%
ROE(5y)-104.4%
ROIC(3y)N/A
ROIC(5y)N/A
STIM Yearly ROA, ROE, ROICSTIM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100 -100 200

1.3 Margins

  • With a Gross Margin value of 48.48%, STIM perfoms like the industry average, outperforming 43.85% of the companies in the same industry.
  • STIM's Gross Margin has declined in the last couple of years.
  • The Profit Margin and Operating Margin are not available for STIM so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 48.48%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-14.01%
GM growth 5Y-8.73%
STIM Yearly Profit, Operating, Gross MarginsSTIM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 40 -40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. STIM Health Analysis

2.1 Basic Checks

  • STIM does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • STIM has more shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, STIM has more shares outstanding
  • STIM has a worse debt/assets ratio than last year.
STIM Yearly Shares OutstandingSTIM Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M
STIM Yearly Total Debt VS Total AssetsSTIM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M

2.2 Solvency

  • STIM has an Altman-Z score of -3.36. This is a bad value and indicates that STIM is not financially healthy and even has some risk of bankruptcy.
  • With a Altman-Z score value of -3.36, STIM is not doing good in the industry: 67.91% of the companies in the same industry are doing better.
  • STIM has a Debt/Equity ratio of 2.94. This is a high value indicating a heavy dependency on external financing.
  • The Debt to Equity ratio of STIM (2.94) is worse than 86.63% of its industry peers.
Industry RankSector Rank
Debt/Equity 2.94
Debt/FCF N/A
Altman-Z -3.36
ROIC/WACCN/A
WACC9.28%
STIM Yearly LT Debt VS Equity VS FCFSTIM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20M -20M 40M 60M 80M

2.3 Liquidity

  • A Current Ratio of 2.02 indicates that STIM has no problem at all paying its short term obligations.
  • STIM's Current ratio of 2.02 is on the low side compared to the rest of the industry. STIM is outperformed by 64.17% of its industry peers.
  • A Quick Ratio of 1.87 indicates that STIM should not have too much problems paying its short term obligations.
  • The Quick ratio of STIM (1.87) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 2.02
Quick Ratio 1.87
STIM Yearly Current Assets VS Current LiabilitesSTIM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. STIM Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 56.93% over the past year.
  • Looking at the last year, STIM shows a very strong growth in Revenue. The Revenue has grown by 99.17%.
  • The Revenue has been growing by 24.81% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)56.93%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%69.7%
Revenue 1Y (TTM)99.17%
Revenue growth 3Y31.76%
Revenue growth 5Y24.81%
Sales Q2Q%85.73%

3.2 Future

  • The Earnings Per Share is expected to grow by 19.09% on average over the next years. This is quite good.
  • The Revenue is expected to grow by 12.54% on average over the next years. This is quite good.
EPS Next Y17.59%
EPS Next 2Y20.28%
EPS Next 3Y19.09%
EPS Next 5YN/A
Revenue Next Year9.73%
Revenue Next 2Y10.82%
Revenue Next 3Y12.92%
Revenue Next 5Y12.54%

3.3 Evolution

  • Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
STIM Yearly Revenue VS EstimatesSTIM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 50M 100M 150M 200M 250M
STIM Yearly EPS VS EstimatesSTIM Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 -0.5 -1 -1.5 -2

More info and screens

Find the best growth stocksShow best growing peers

0

4. STIM Valuation Analysis

4.1 Price/Earnings Ratio

  • STIM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for STIM. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
STIM Price Earnings VS Forward Price EarningsSTIM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
STIM Per share dataSTIM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 1.5 2

4.3 Compensation for Growth

  • A more expensive valuation may be justified as STIM's earnings are expected to grow with 19.09% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y20.28%
EPS Next 3Y19.09%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. STIM Dividend Analysis

5.1 Amount

  • STIM does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

STIM Fundamentals: All Metrics, Ratios and Statistics

NEURONETICS INC

NASDAQ:STIM (4/24/2026, 8:09:41 PM)

After market: 1.7 +0.02 (+1.19%)

1.68

-0.01 (-0.59%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)03-17
Earnings (Next)05-05
Inst Owners34.41%
Inst Owner Change-0.09%
Ins Owners21.41%
Ins Owner Change25.79%
Market Cap116.89M
Revenue(TTM)149.16M
Net Income(TTM)-39.00M
Analysts82.22
Price Target4.42 (163.1%)
Short Float %34.91%
Short Ratio3.82
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)3.74%
Min EPS beat(2)-0.62%
Max EPS beat(2)8.09%
EPS beat(4)1
Avg EPS beat(4)-37.26%
Min EPS beat(4)-91.81%
Max EPS beat(4)8.09%
EPS beat(8)2
Avg EPS beat(8)-36.98%
EPS beat(12)5
Avg EPS beat(12)-17.97%
EPS beat(16)8
Avg EPS beat(16)-9.46%
Revenue beat(2)1
Avg Revenue beat(2)-1.33%
Min Revenue beat(2)-3.39%
Max Revenue beat(2)0.72%
Revenue beat(4)3
Avg Revenue beat(4)1.67%
Min Revenue beat(4)-3.39%
Max Revenue beat(4)7.85%
Revenue beat(8)4
Avg Revenue beat(8)0.02%
Revenue beat(12)6
Avg Revenue beat(12)0%
Revenue beat(16)10
Avg Revenue beat(16)1.29%
PT rev (1m)-33.33%
PT rev (3m)-33.33%
EPS NQ rev (1m)-33.33%
EPS NQ rev (3m)-33.33%
EPS NY rev (1m)-3.62%
EPS NY rev (3m)-3.62%
Revenue NQ rev (1m)-8.19%
Revenue NQ rev (3m)-8.19%
Revenue NY rev (1m)-0.37%
Revenue NY rev (3m)-1.03%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.78
P/FCF N/A
P/OCF N/A
P/B 5.22
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.59
EYN/A
EPS(NY)-0.49
Fwd EYN/A
FCF(TTM)-0.3
FCFYN/A
OCF(TTM)-0.29
OCFYN/A
SpS2.14
BVpS0.32
TBVpS-0.28
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -27.55%
ROE -174.27%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 48.48%
FCFM N/A
ROA(3y)-28.21%
ROA(5y)-27.7%
ROE(3y)-140.11%
ROE(5y)-104.4%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-14.01%
GM growth 5Y-8.73%
F-Score4
Asset Turnover1.05
Health
Industry RankSector Rank
Debt/Equity 2.94
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 23.12%
Cap/Sales 0.54%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.02
Quick Ratio 1.87
Altman-Z -3.36
F-Score4
WACC9.28%
ROIC/WACCN/A
Cap/Depr(3y)70.64%
Cap/Depr(5y)126.36%
Cap/Sales(3y)1.94%
Cap/Sales(5y)3.02%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)56.93%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%69.7%
EPS Next Y17.59%
EPS Next 2Y20.28%
EPS Next 3Y19.09%
EPS Next 5YN/A
Revenue 1Y (TTM)99.17%
Revenue growth 3Y31.76%
Revenue growth 5Y24.81%
Sales Q2Q%85.73%
Revenue Next Year9.73%
Revenue Next 2Y10.82%
Revenue Next 3Y12.92%
Revenue Next 5Y12.54%
EBIT growth 1Y-2.85%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year61.28%
EBIT Next 3Y28.71%
EBIT Next 5Y17.59%
FCF growth 1Y34.77%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y34.27%
OCF growth 3YN/A
OCF growth 5YN/A

NEURONETICS INC / STIM Fundamental Analysis FAQ

What is the ChartMill fundamental rating of NEURONETICS INC (STIM) stock?

ChartMill assigns a fundamental rating of 2 / 10 to STIM.


What is the valuation status of NEURONETICS INC (STIM) stock?

ChartMill assigns a valuation rating of 0 / 10 to NEURONETICS INC (STIM). This can be considered as Overvalued.


What is the profitability of STIM stock?

NEURONETICS INC (STIM) has a profitability rating of 1 / 10.